Besivance

Besivance is a brand name of besifloxacin ophthalmic, approved by the FDA in the following formulation(s):

BESIVANCE (besifloxacin hydrochloride - suspension/drops; ophthalmic)

• 
  Manufacturer: BAUSCH AND LOMB
  
  Approval date: May 28, 2009
  
  Strength(s): EQ 0.6% BASE ^[RLD]

Has a generic version of Besivance been approved?

No. There is currently no therapeutically equivalent version of Besivance available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Besivance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Quinolone carboxylic acid derivatives
  Patent 5,447,926
  Issued: September 5, 1995
  Inventor(s): Konno; Fujiko & Shibata; Akihiro & Matsuda; Hideaki & Asaoka; Takemitsu & Kawahara; Ryuichi & Taido; Naokata & Kuraishi; Tasdayuki & Takeda; Sunao
  Assignee(s): SS Pharmaceutical Co., Ltd.
  A quinolone carboxylic acid derivative having the following formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an aralkyl group, an ester residual group which can be hydrolyzed in living bodies, R.sup.2 is a hydrogen atom or an amino group which may be substituted by one or two lower alkyl groups, X is a hydrogen atom or a halogen atom, Y is CH.sub.2, O, S, SO, SO.sub.2, or N--R.sup.3, wherein R.sup.3 is a hydrogen atom or a lower alkyl group, and Z is an oxygen atom or two hydrogen atoms; or a salt thereof; and an antimicrobial agent comprising the same. The compound exhibits a superior antimicrobial activity, especially against gram positive microorganisms, and is thus useful for the treatments and prevention of various infectious diseases in clinics.
  
  Patent expiration dates:
  
  
  • September 5, 2012
    
    ✓ 
    Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Quinolone carboxylic acid compositions and related methods of treatment
  Patent 6,685,958
  Issued: February 3, 2004
  Inventor(s): Samir; Roy & Santosh Kumar; Chandrasekaran & Katsumi; Imamori & Takemitsu; Asaoka & Akihiro; Shibata & Masami; Takahashi & Lyle M.; Bowman
  Assignee(s): InSite Vision Incorporated
  SSP Co., Ltd.
  The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
  
  Patent expiration dates:
  
  
  • June 29, 2021
    
    ✓ 
    Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
    ✓ 
    Drug product
  
  



• 
  Quinolone carboxylic acid compositions and related methods of treatment
  Patent 6,699,492
  Issued: March 2, 2004
  Inventor(s): Samir; Roy & Santosh Kumar; Chandrasekaran & Katsumi; Imamori & Takemitsu; Asaoka & Akihiro; Shibata & Masami; Takahashi & Lyle M.; Bowman
  Assignee(s): InSite Vision Incorporated
  SSP Co., Ltd.
  The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
  
  Patent expiration dates:
  
  
  • March 31, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 28, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Besivance Consumer Information (Drugs.com)
• Besivance Drops Consumer Information (Wolters Kluwer)
• Besivance Consumer Information (Cerner Multum)
• Besivance Advanced Consumer Information (Micromedex)
• Besivance AHFS DI Monographs (ASHP)
• Besifloxacin Drops Consumer Information (Wolters Kluwer)
• Besifloxacin ophthalmic Consumer Information (Cerner Multum)
• Besifloxacin Ophthalmic Advanced Consumer Information (Micromedex)
• Besifloxacin Hydrochloride AHFS DI Monographs (ASHP)